Advances in Neoadjuvant and Combination Therapies for Locally Advanced Head and Neck Squamous Cell Carcinoma
DOI:
https://doi.org/10.54097/p5hr2n19Keywords:
Neoadjuvant Therapy, Immunotherapy Combination Therapy, Chemotherapy, Targeted Therapy, Locally Advanced Head and Neck Squamous Cell CarcinomaAbstract
Current treatment modalities for locally advanced head and neck squamous cell carcinoma (HNSCC) are increasingly diverse. The CSCO guidelines for head and neck cancer diagnosis and treatment indicate that neoadjuvant therapy followed by radical surgery has become one of the recommended treatment strategies. In recent years, immune checkpoint inhibitors (ICIs) have been discovered and applied in the treatment of locally advanced HNSCC, achieving promising results. Most patients receiving ICI monotherapy or ICI combined with targeted or chemotherapeutic agents for 2-4 cycles demonstrate improved event-free survival (EFS), major pathological response (MPR) rates, clinical complete response (CR) rates, and partial response (PR) rates. Additionally, these regimens significantly help control adverse reactions. Given the heterogeneity of the tumor microenvironment across individual patients, selecting the most suitable personalized treatment plan from various options is a current research priority. This article analyzes neoadjuvant strategies involving upfront systemic therapy for locally advanced HNSCC, exploring the sequence of different agents and subsequent treatment plans.
Downloads
References
[1] Yu Y, Jiao Z ,Wu T , et al. Comparison of induction chemotherapy with/without PD-1 inhibitors followed by concurrent chemoradiotherapy in locally advanced head and neck squamous cell carcinoma[J].Cancer Immunology, Immunotherapy,2026,75(1):35-35.DOI:10.1007/S00262-025-04284-W.
[2] Zhang Hongwei, Xue Rong, Zhu Lan, et al. Relationship between the infiltration level of infiltrating memory B cells in head and neck squamous cell carcinoma tissues and the prognosis of immunotherapy[J]. Chinese Journal of Immunology, 2025, 41(12): 2905-2912.
[3] Lan T, Tan Y ,Shi H , et al. Deep learning enhanced MRI radiomics in predicting pathologic response of head and neck squamous carcinoma to neoadjuvant chemoimmunotherapy: a retrospective analysis.[J].International journal of surgery (London, England),2025,DOI: 10.1097/JS9. 000000000000 3710.
[4] Tan L ,Zhang H ,Huang W , et al. 1422P A single-center, observational, phase II clinical study of PD-1 inhibitor or cetuximab combined with chemotherapy for neoadjuvant treatment of recurrent, resectable head and neck squamous cell carcinoma[J].Annals of Oncology,2025,36(S2):S868-S868. DOI: 10.1016/J.ANNONC.2025.08.2054.
[5] Chen J, Zhang JN, Kuang YY, et al. Application of neoadjuvant immunotherapy in head and neck squamous cell carcinoma: from mechanism to clinical practice [J/OL]. Journal of Central South University (Medical Edition), 1-13 [2026-01-23]. https://link.cnki.netUrlid/43.1427.R.20250827.0918.006.
[6] Ning Y, Song Y ,He Y , et al. Effective imaging examination evaluation method for surgical pathological complete responds of head and neck squamous cell carcinoma after neoadjuvant immunochemotherapy[J].Frontiers in Oncology, 2025, 15158 5194-1585194. DOI:10.3389/ FONC.2025.1585194.
[7] Ning D Y, Song X Y ,He Q Y , et al. Discordant Responses Between Imaging Examination and Surgical Pathology of Head and Heck Squamous Cell Carcinoma After Neoadjuvant Immunotherapy Combined With Chemotherapy.[J].World journal of oncology,2025,16(1):59-69.DOI:10.14740/ WJON 1973.
[8] Guo Ye, Zhang Chenping. Expert consensus on immune checkpoint inhibitor therapy for recurrent/metastatic head and neck squamous cell carcinoma (2024 edition) [J]. China Cancer Journal, 2024,34(04):425-438. DOI: 10.19401/j.cnki.1007-3639.2024.04.010.
[9] Yang Yuyan, Xia Lei. Research progress on neoadjuvant immunotherapy monotherapy or combination therapy for locally advanced squamous cell carcinoma of the head and neck [J]. Journal of Immunology, 2024,40(01):104-111. DOI: 10. 13431/j.cnki.immunol.j.20240000.
[10] Susanne W, Gunnar W ,Jeannette V , et al. Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial.[J].Frontiers in oncology, 2023,131128176-1128176. DOI: 10.3389/FONC. 2023. 11281 76.
[11] Kai W, Lin G ,Haizhen L , et al. Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas.[J].Frontiers in immunology, 2023, 141189752-1189752.DOI:10.3389/FIMMU.2023.1189752.
[12] Liu Lei, Xiang Zhongzheng, Li Yi, et al. Expert consensus on immune checkpoint inhibitors for the treatment of head and neck squamous cell carcinoma [J]. West China Journal of Stomatology, 2022,40(06):619-628.
[13] Martina A S ,Gerwin H ,Erwin T , et al. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.[J].Journal for immunotherapy of cancer,2022,10(3):DOI:10.1136/JITC-2021-003420.
[14] Liping W, Gui Y ,Guohong L , et al. Identification of lncRNA Signature of Tumor-Infiltrating T Lymphocytes With Potential Implications for Prognosis and Chemotherapy of Head and Neck Squamous Cell Carcinoma[J].Frontiers in Pharmacology, 2022,12795205-795205.DOI:10.3389/FPHAR.2021.795205.
[15] M. K B, W. J L ,Elena G , et al. Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma[J].Cancers,2021,13(22):5733-5733.DOI: 10.3390/CANCERS13225733.
[16] Rebekka D, Carmen M B ,K. A F, et al. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells[J].Nature Communications, 2021, 12(1):1047-1047.DOI:10.1038/S41467-021-21383-1.
[17] Panagiota E, Maria A ,George P , et al. Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)[J]. Cancers,2021, 13(2): 286-286. DOI:10.3390/CANCERS13020286.
[18] Andrei B, Richard C ,Anshuman C . PD-L1 testing and immunotherapy selection - early laboratory experience and its potential role in head and neck cancer management.[J].Archive of clinical cases,2021,8(1):14-18.DOI:10.22551/ 2021.30. 0801. 10179.
[19] Barbara S, Chiara M ,Bo Y , et al. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.[J].International journal of molecular sciences, 2020, 21(19):7032-7032.DOI:10.3390/ijms21197032.
[20] Eduardo M, P C R ,C M K , et al. A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.[J].Clinical cancer research : an official journal of the American Association for Cancer Research,2018,24(12):2740-2748.DOI:10.1158/1078-0432. CCR- 17-3796.
[21] Hasan M ,Kıvrak D S ,Şeyda G , et al. Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?[J].Journal of cancer research and therapeutics,2017,13(3):510-513.DOI:10.4103/0973-1482. 161933.
[22] Zhang X ,Liu Z ,Liu X , et al. Influence of pathologic complete response to neoadjuvant chemotherapy on long-term survival of patients with advanced head and neck squamous cell carcinoma[J].Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology,2013,115(2):218-223.DOI:10. 1016/j.oooo. 2012. 09.084.
[23] Zhang, X.-R. ,Liu , et al. Influence of pathologic complete response to neoadjuvant chemotherapy on long-term survival of patients with advanced head and neck squamous cell carcinoma[J].Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics,2013,115(2):218-223.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
